Skip to main content
SpringerLink
Log in

The prevalence and the clinical relevance of anti-Ro52 in Korean patients with primary Sjögren’s syndrome

  • Short Communication
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

So far, there was no report on the prevalence and clinical relevance of anti-Ro52 in primary Sjögren’s syndrome (pSS) patients in Korea. In this study, we investigated the prevalence and the clinical relevance of anti-Ro52 in Korean patients with pSS. We retrospectively reviewed the medical records of 96 patients with pSS. On the first visit clinical manifestations, laboratory features and autoantibodies were assessed. We divided subjects into 4 groups according to the presence of anti-Ro60 or anti-Ro52 and investigated the association between those autoantibodies and clinical manifestations. Anti-Ro52 (66.7%) was the most frequently detected autoantibody, followed by anti-Ro60 (52.1%) and anti-La (49.0%). Patients with anti-Ro52 had higher frequency of liver and muscle involvements than those without, while anti-Ro60 exhibited negative association with liver involvement. Anti-Ro52 showed significant relative risk for liver involvement (OR = 5.987, P = 0.038, 95% CI = 1.109–32.326), while anti-Ro60 showed inverse relative risk for liver involvement (OR = 0.122, P = 0.003, 95% CI = 0.031–0.479). Anti-Ro52 also showed significant OR for muscle involvement (OR = 9.533, P = 0.044, 95% CI = 1.059–85.793). In conclusion, anti-Ro52 was the most frequently detected autoantibody except ANA in patients with pSS in Korea. Anti-Ro52 was significantly associated with liver and muscle involvements, while anti-Ro60 was inversely associated with liver involvement in Korean patients with pSS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Haldorsen K, Moen K, Jacobsen H, Jonsson R, Brun JG (2008) Exocrine function in primary Sjögren syndrome: natural course and prognostic factors. Ann Rheum Dis 67:949–954

    Article  PubMed  CAS  Google Scholar 

  2. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (2008) Rheumatology, 4th edn. MOSBY, London, pp 1341–1351

    Google Scholar 

  3. Schulte-Pelkum J, Fritzler M, Mahler M (2009) Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev 8:632–637

    Article  PubMed  CAS  Google Scholar 

  4. Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558

    Article  PubMed  CAS  Google Scholar 

  5. Peene I, Meheus L, De Keyser S, Humbel R, Veys EM, De Keyser F (2002) Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease. Ann Rheum Dis 61:929–933

    Article  PubMed  CAS  Google Scholar 

  6. Fritsch C, Hoebeke J, Dali H, Ricchiuti V, Isenberg DA, Meyer O, Muller S (2006) 52-kDa Ro/SSA epitopes preferentially recognized by antibodies from mothers of children with neonatal lupus and congenital heart block. Arthritis Res Ther 8:R4

    Article  PubMed  Google Scholar 

  7. Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senécal JL (2007) Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 9:R78

    Article  PubMed  Google Scholar 

  8. Peene I, Meheus L, Veys EM, De Keyser F (2002) Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to the detailed serotype. Ann Rheum Dis 61:1090–1094

    Article  PubMed  CAS  Google Scholar 

  9. Gál I, Lakos G, Zeher M (2000) Comparison of the anti-Ro/SSA autoantibody profile between patients with primary and secondary Sjögren’s syndrome. Autoimmunity 32:89–92

    Article  PubMed  Google Scholar 

  10. Meheus L, van Venrooij WJ, Wiik A et al (1999) Multicenter validation of recombinant, natural and synthetic antigens used in a single multiparameter assay for the detection of specific anti-nuclear autoantibodies in connective tissue disorders. Clin Exp Rheumatol 17:205–214

    PubMed  CAS  Google Scholar 

  11. Fujimoto M, Shimozuma M, Yazawa N et al (1997) Prevalence and clinical relevance of 52-kDa and 60- kDa Ro/SS-A autoantibodies in Japanese patients with systemic sclerosis. Ann Rheum Dis 56:667–670

    Article  PubMed  CAS  Google Scholar 

  12. Hervier B, Rimbert M, Colonna F, Hamidou MA, Audrain M (2009) Clinical significance of anti-Ro/SSA- 52 kDa antibodies: a retrospective monocentric study. Rheumatology (Oxford) 48:964–967

    Article  CAS  Google Scholar 

  13. Chisholm DM, Mason DK (1968) Labial salivary gland biopsy in Sjögren’s syndrome. J Clin Pathol 21:656–660

    Article  PubMed  CAS  Google Scholar 

  14. Burbelo PD, Ching KH, Issa AT et al (2009) Rapid serological detection of autoantibodies associated with Sjögren’s syndrome. J Transl Med 7:83

    Article  PubMed  Google Scholar 

  15. López-Longo FJ, Rodríguez-Mahou M, Escalona-Monge M, González CM, Monteagudo I, Carreño-Pérez L (2003) Simultaneous identification of various antinuclear antibodies using an automated multiparameter line immunoassay system. Lupus 12:623–629

    Article  PubMed  Google Scholar 

  16. Locht H, Pelck R, Manthorpe R (2008) Diagnostic and prognostic significance of measuring antibodies to alpha-fodrin compared to anti-Ro-52, anti-Ro-60, and anti-La in primary Sjögren’s syndrome. J Rheumatol 35:845–849

    PubMed  Google Scholar 

  17. Ramos-Casals M, García-Carrasco M, Cervera R et al (2001) Hepatitis C virus infection mimicking primary Sjögren syndrome. A clinical and immunologic description of 35 cases. Medicine (Baltimore) 80:1–8

    Article  CAS  Google Scholar 

  18. Ceribelli A, Cavazzana I, Cattaneo R, Franceschini F (2008) Hepatitis C virus infection and primary Sjögren’s syndrome: a clinical and serologic description of 9 patients. Autoimmun Rev 8:92–94

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the Chung-Ang University Research Grant in 2009.

Author information

Author notes

  1. Sang-Won Lee

    Present address: Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea

Authors and Affiliations

  1. Department of Rheumatology, Chung-Ang University College of Medicine, 224-1 Heuksuk-dong, Dongjak-gu, 156-755, Seoul, South Korea

    Jung-Soo Song & Sang-Won Lee

  2. Division of Gastroenterology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea

    Jae Hyuk Do

Authors
  1. Jung-Soo Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jae Hyuk Do
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sang-Won Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jung-Soo Song.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Song, JS., Do, J.H. & Lee, SW. The prevalence and the clinical relevance of anti-Ro52 in Korean patients with primary Sjögren’s syndrome. Rheumatol Int 32, 491–495 (2012). https://doi.org/10.1007/s00296-010-1790-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-010-1790-x

Keywords

Search

Navigation